Cue Biopharma, Inc.
NASDAQ:CUEBiotechnology
+$0.38 today
- Market cap
- $102.43M
- Beta
- 2.53
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$4.06
Volume 0.21M
Average 0.74M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Cue Biopharma, Inc.
NASDAQ:CUE
Intrinsic Alpha fair value
Locked
Current Price
$14.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +180.5% | -22.3% (5yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +180.5% over three years. Forward estimates point to Revenue at -22.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Century Therapeutics, Inc. NASDAQ:IPSC | $298.77M | $1.65 | Not rated | -1.8 | +169.00% |
Spruce Biosciences, Inc. NASDAQ:SPRB | $124.47M | $43.31 | Not rated | -1.9 | -60.54% |
Outlook Therapeutics, Inc. NASDAQ:OTLK | $100.54M | $0.41 | Not rated | -2.1 | -78.67% |
NRx Pharmaceuticals, Inc. NASDAQ:NRXP | $94.82M | $2.19 | Not rated | -5.3 | +25.62% |
Equillium, Inc. NASDAQ:EQ | $81.80M | $1.29 | Not rated | -15.3 | +10.89% |
Coeptis Therapeutics, Inc. NASDAQ:COEP | $38.62M | $10.99 | Not rated | -8.3 | -10.24% |
Continue the stock analysis
Jump to another research area for this company.